| Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? | |
| | |
MedLine Citation:
|
PMID: 17484034 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Extensive experimental data have revealed a central role for oxidative stress in atherogenesis and suggested a potential role for 'antioxidant' treatment in cardiovascular disease (CVD) [1-11]. Experimental data, however, have not translated into clinical benefit: most antioxidant vitamin trials have failed to reduce cardiovascular morbidity and mortality [12]. Moreover, recent clinical trials have suggested that mono-therapy with certain antioxidant vitamins like vitamin E may, in fact, be detrimental [13]. As a result of the disappointing outcome of 'antioxidant' vitamin trials, some authors have questioned both the utility of 'antioxidant' treatment in CVD and the supposedly central role of oxidative stress in atherogenesis [14-19]. Other investigators, however, sustain that the beneficial effects of lipid lowering and anti-hypertensive treatment are at least, in part, due to their 'antioxidant' properties, in addition to their specific pharmacological properties [20, 21]. Oxidant stress plays a pivotal role in atherogenesis, however, the clinical promise of antioxidant vitamins has failed to translate into clinical benefit. Increasing evidence suggests that more rigorous clinical trial designs are necessary to effectively divulge antioxidant utility and that a multifaceted antioxidant approach to atherosclerosis may yield the most clinical reward. This article reviews currently available evidence on the role of oxidant stress in atherosclerosis, analyzes the results of large anti-oxidant trials, and suggests ways to investigate the true role of antioxidant treatment in the clinical setting. |
| | |
Authors:
|
Mika J Thomson; Valentina Puntmann; Juan-Carlos Kaski |
Related Documents
:
|
23456784 - A review of the evidence regarding associations between attachment theory and experimen... 18547654 - Glia in pathological pain: a role for fractalkine. 9800114 - Surgery for gynecologic malignancies. 11400084 - Operation for acute peripheral arterial occlusion: is it still the gold standard? 22198694 - Improvement in pain intensity, spine stiffness, and mobility during a controlled indivi... 12004694 - Pseudo-dental pain and sensitivity to percussion. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 21 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-05-24 Completed Date: 2007-10-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 195-210 Citation Subset: IM |
Affiliation:
|
Cardiac and Vascular Sciences, St George's, University of London, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antioxidants / adverse effects, therapeutic use* Atherosclerosis / drug therapy*, metabolism, physiopathology Endothelium, Vascular / drug effects, physiopathology Humans Models, Biological Oxidative Stress / drug effects Reactive Oxygen Species / metabolism* Treatment Failure Vitamin E / adverse effects, therapeutic use* Vitamins / adverse effects, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/Reactive Oxygen Species; 0/Vitamins; 1406-18-4/Vitamin E |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Familial aggregation of forearm bone mineral density in Chinese.
Next Document: Oral administration of candesartan improves the survival of mice with viral myocarditis through modi...